BidaskClub Downgrades MediciNova (MNOV) to Hold
MediciNova (NASDAQ:MNOV) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.
Shares of MNOV opened at $11.12 on Friday. The firm has a market cap of $523.07 million, a price-to-earnings ratio of -34.75 and a beta of 0.31. MediciNova has a twelve month low of $5.81 and a twelve month high of $14.50.
MediciNova (NASDAQ:MNOV) last announced its quarterly earnings results on Monday, July 23rd. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.04. As a group, equities research analysts expect that MediciNova will post -0.44 earnings per share for the current fiscal year.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Featured Article: Yield Curve
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.